NCCN 2019 Nursing Program: Advancing Oncology Nursing™
The NCCN 2019 Nursing Program at the NCCN Annual Conference will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting. The program agenda includes the following topics: Integrating Evidence-Based Practice in Oncology Nursing, Evidence-Based Strategies for the Management of Central Venous Catheters, Recognizing Malnutrition and Recommendations for Interventions, Best Practices in Immunotherapy Symptom Management and Patient Education as well as Clinical Updates for Head and Neck Cancers, Primary Therapy of Multiple Myeloma and Metastatic Colorectal Cancer.
This educational program is designed to meet the educational needs of oncology nurses who manage patients with cancer.
Following this program, participants should be able to:
Integrating Evidence-based Practice into Oncology Nursing
• Discuss the impact of Evidence-based Practice (EBP) in ensuring quality and value in oncology care
• Outline the process of developing institutional EBP projects to demonstrate efficacy, sustainability and return on investment
• Identify existing programs that can be utilized to implement hospital-wide standardized approaches to EBP
Evidence-based Strategies for the Management of Central Venous Catheters
• Identify different types of central venous catheters or vascular access devices used in oncology care and outline their associated functions
• Discuss evidence-based strategies for the care and maintenance of vascular access devices
• Outline evidence-based strategies to address complications associated with central venous catheters using insertion and maintenance bundles
Clinical Updates: Head and Neck Cancers
• Recognize supportive care needs of patients undergoing treatment for head and neck (H&N) cancer
• Understand differences between HPV-positive and HPV-negative oropharyngeal cancer
• Identify immunotherapy agents that are recommended for treatment of recurrent or metastatic H&N cancer, as well as adverse effects associated with these agents
Clinical Updates: Primary Therapy of Multiple Myeloma
• Discuss the rationale behind inclusion of new options for primary and bone-directed therapy in the NCCN Guidelines for Multiple Myeloma
• Outline appropriate evidence-based management strategies for patients with newly diagnosed multiple myeloma taking patient characteristics into consideration
• Learn the various adverse effects associated with multiple myeloma therapies reported in pivotal clinical studies
Clinical Updates: Metastatic Colon Cancer
• Describe current treatment approaches for patients with metastatic colorectal cancer
• Explain results of recent clinical trials for new treatment options for metastatic colorectal cancer
• Discuss how newly-approved therapies and emerging treatment approaches may be incorporated into clinical practice, including supportive care considerations
Recognizing Malnutrition and Recommendations for Interventions
• List risk factors for malnutrition in patients with cancer
• Discuss the importance of early malnutrition screening in all patients with cancer, regardless of BMI and weight history
• Describe examples of nurse-led interventions for malnourished and at-risk patients with cancer
Best Practices in Immunotherapy Symptom Management and Patient Education
• Understand the scope and presentation of immunotherapy-related toxicity
• Assess patients on immunotherapy for potential irAEs
• Apply the NCCN Guidelines for managing irAEs
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses no relevant financial relationships:
Nancy G. Houlihan, MA, RN, AOCN
Yi Lisa Hwa, APRN, CNP, DNP
Rhone M. Levin, MEd, RDN, CSO, LD, FAND
Colleen O'Leary, MSN, RN, AOCNS
MiKaela Olsen, APRN-CNS, MS, AOCNS, FAAN
Nicole M. Ross, MSN, CRNP, AOCNP
Colleen K. Spees, PhD, MEd, RDN, LD, FAND
The faculty listed below discloses the following relevant financial relationships:
Marianne Davies, DNP, RN, CNS, ACNP-BC, AOCNP
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Bristol-Myers Squibb Company: Product/Speakers Bureau
Genentech, Inc.: Product/Speakers Bureau
Merck & Co., Inc.: Product/Speakers Bureau
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (Employed by NCCN until 8/10/18); Wui-Jin Koh, MD; Joan S. McClure, MS (Employed by NCCN until 8/1/18); Lisa Perfidio, MS; Sarah Sinclair; Kathy Ann Smith, CHCP; Gary J. Weyhmuller, MBA, SPHR
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Susan D. Darlow, PhD; Deborah A. Freedman-Cass, PhD; Lisa Gurski, PhD; Rashmi Kumar, PhD; Ndiya Ogba, PhD; Jillian Scavone, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this educational activity for a maximum of 5.25 contact hours.
- 5.25 ANCC contact hours
- 5.25 Participation